|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-11-1
|
|
pubmed:abstractText |
Serum erythropoietin level less than 100U/L and a transfusion requirement of less than 2 units per month are the best predictive factors for response to treatment by erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. To investigate the factors influencing the response to erythropoiesis-stimulating agents, we enrolled 127 low/int-1 myelodysplastic syndrome patients at diagnosis in a biological study of erythropoiesis. The 54 non-responders had a significantly lower number of burst-forming unit-erythroid and colony-forming unit-erythroid than responders. Erythropoietin-dependent proliferation and survival, and phospho (p)-ERK1/2 expression in steady state and after erythropoietin stimulation were defective in cultured erythroblasts. By flow cytometry, p-ERK1/2 was significantly lower in bone marrow CD45(-)/CD71(+)/GPA(-)cells from non-responders compared to responders or controls. Receiver Operator Characteristic curve analysis showed that this flow cytometry test was a sensitive biomarker for predicting the response to erythropoiesis-stimulating agents.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1964-8
|
|
pubmed:meshHeading |
pubmed-meshheading:20823131-Aged,
pubmed-meshheading:20823131-Aged, 80 and over,
pubmed-meshheading:20823131-Biological Markers,
pubmed-meshheading:20823131-Cell Proliferation,
pubmed-meshheading:20823131-Cells, Cultured,
pubmed-meshheading:20823131-Erythroblasts,
pubmed-meshheading:20823131-Erythropoiesis,
pubmed-meshheading:20823131-Erythropoietin,
pubmed-meshheading:20823131-Female,
pubmed-meshheading:20823131-Flow Cytometry,
pubmed-meshheading:20823131-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:20823131-Hematinics,
pubmed-meshheading:20823131-Humans,
pubmed-meshheading:20823131-Male,
pubmed-meshheading:20823131-Mitogen-Activated Protein Kinase 1,
pubmed-meshheading:20823131-Mitogen-Activated Protein Kinase 3,
pubmed-meshheading:20823131-Myelodysplastic Syndromes
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes.
|
|
pubmed:affiliation |
Département d’Immunologie-Hématologie, Institut Cochin, INSERM U1016, 3Centre National de la Recherche Scientifique, Paris Cedex 14, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't
|
